Targeting the metabolic machinery that fuels cancer stem cells represents a critical frontier in treating acute myeloid leukemia, where resistant stem cell populations drive relapse and treatment failure. New findings reveal that disrupting a specific microRNA pathway can dramatically enhance the effectiveness of existing therapies by attacking the energy systems these dangerous cells depend upon.
Researchers identified microRNA-126 as a master regulator maintaining leukemic stem cell survival through control of mitochondrial metabolism. The microRNA sustains BCL-2 protein levels, which promote fatty acid oxidation and oxidative phosphorylation—the preferred energy pathways of these resilient cancer cells. When miR-126 function was blocked using miRisten, an experimental CpG-conjugated inhibitor currently in clinical trials, leukemic stem cells experienced severe metabolic disruption. Their mitochondria shifted from protective fusion states to damaging fragmentation, ultimately triggering cell death pathways.
The combination of miRisten with venetoclax, an approved BCL-2 inhibitor, produced synergistic anti-cancer effects in laboratory models using patient-derived leukemia samples. This pairing enhanced the standard venetoclax-azacitidine regimen used for older patients, significantly extending survival times and reducing stem cell burden. Most importantly, the combination restored sensitivity to venetoclax in resistant cases.
This approach represents a sophisticated metabolic targeting strategy rather than conventional chemotherapy. By simultaneously attacking energy production and mitochondrial integrity, the combination exploits fundamental vulnerabilities specific to cancer stem cells. While promising, the findings require validation in human trials to determine whether metabolic disruption can translate into durable clinical responses without excessive toxicity to normal stem cells.